科研之友
微信
新浪微博
Facebook
分享链接
摘要
Stroke is the leading cause of morbidity and mortality in patients with atrial fibrillation. whereas warfarin reduces the risk of stroke, its interactions with other drugs and food, individual differences in its efficacy and the need for frequent monitoring make its use inconvenient. dabigatran etexilate might represent a step forward in the care of patients with atrial fibrillation.
- 出版日期2010-1
